Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

Yiru Yan, Jinqin Liu, Songyang Zhao, Fuhui Li, Lin Yang, Zefeng Xu, Tiejun Qin, Xiaofan Zhu, Wenbin An, Zhongxun Shi, Wenyi Shen, Peihong Zhang, Gang Huang, Raajit K. Rampal, Zhijian Xiao, Bing Li

Blood blood.2025028703.

https://doi.org/10.1182/blood.2025028703

Published: 2025

Includes: Supplemental data

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Yujiao Jia, Haoxu Wang, Bingqing Huang, Li Qin, Jiao Chang, Ruixue Zhang, Jinqin Liu, Hui Wei, Jianxiang Wang, Jun Shi, Qi Sun, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2025-3499

Published: 2025

Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood (2025) 146 (Supplement 1): 908.

https://doi.org/10.1182/blood-2025-908

Published: 2025

Journal Articles

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Blood (2025) 146 (Supplement 1): 235.

https://doi.org/10.1182/blood-2025-235

Published: 2025

Journal Articles

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Xin Wang, Qiujin Shen, Saibing Qi, Xiaowen Gong, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Binhan Jiang, Yue Zhong, Lijuan Pan, Meng Jiao, Qingyan Gao, Robert Gale, Junren Chen, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 7385.

https://doi.org/10.1182/blood-2025-7385

Published: 2025

Journal Articles

Transfusion dependence is associated with poor survival in MDS-h and MDS-LB, while transplantation improves outcomes

Wenjing Guo, Linlin Liu, Li Jia, Hui Wang, Aiming Pang, Erlie Jiang, Zhijian Xiao, Sizhou Feng

Blood (2025) 146 (Supplement 1): 7381.

https://doi.org/10.1182/blood-2025-7381

Published: 2025

Journal Articles

Research on co-mutated genes in FLT3-ITD-positive acute myeloid leukemia

Li Wan, Yujiao Jia, Yan Li, Jiao Ma, Haiwei Li, Yao Yao, Hui Wei, Jianxiang Wang, Zhijian Xiao, Yingchang Mi

Blood (2025) 146 (Supplement 1): 7027.

https://doi.org/10.1182/blood-2025-7027

Published: 2025

Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Blood (2025) 146 (Supplement 1): 907.

https://doi.org/10.1182/blood-2025-907

Published: 2025

Journal Articles

Molecular and clinical characteristics of NUP98 rearrangements and their therapeutic responses in 6,000 patients with hematologic malignancies

Bingqing Huang, Yujiao Jia, Haoxu Wang, Li Qin, Hui Wei, Xiaofan Zhu, Jianxiang Wang, Qi Sun, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2025-3469

Published: 2025

Journal Articles

The efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor AND017 in NUP98-HOXD13transgenic mouse

Fuhui LI, Jinqin Liu, Lin Yang, Gang Huang, Bing Li, Zhijian Xiao

Blood (2025) 146 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2025-3273

Published: 2025

Journal Articles

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Blood (2025) 146 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2025-5584

Published: 2025

Journal Articles

Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A :: MLLT3 and U2AF1 mutation

Shuying Chen, Zhijian Xiao

Blood (2025) 146 (6): 765.

https://doi.org/10.1182/blood.2025029617

Published: 2025

Journal Articles

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

Bing Li, Yanping Zeng, Chengwen Li, Jinqin Liu, Ge Song, Yao Yao, Amer M. Zeidan, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6707.

https://doi.org/10.1182/blood-2024-205429

Published: 2024

Journal Articles

Trial in Progress: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination with Azacitidine in Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes (AK117-205)

Amer M. Zeidan, Hongyan Tong, Zhijian Xiao, Praneeth Baratam, Ramzi Abboud, Christopher B. Benton, Joshua F Zeidner, Uma Borate, Wanxing Chai-Ho, Yonglin Lu, Jie Yang, Mingxiu Hu, Baiyong Li, Michelle Xia, David Sallman

Blood (2024) 144 (Supplement 1): 6705.

https://doi.org/10.1182/blood-2024-200541

Published: 2024

Journal Articles

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Fuhui Li, Yudi Zhang, Chengwen Li, Qi Sun, Jinqin Liu, Tiejun Qin, Zefeng Xu, Bing Li, Shiqiang Qu, Lijuan Pan, Qingyan Gao, Meng Jiao, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6734.

https://doi.org/10.1182/blood-2024-200761

Published: 2024

Journal Articles

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xin Wang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Bing Li, Li Juan Pan, Qingyan Gao, Meng Jiao, Jinying Zhao, Wenjun Xie, Robert Peter Gale, Zhijian Xiao

Blood (2024) 144 (Supplement 1): 6729.

https://doi.org/10.1182/blood-2024-199104

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The role of CD38 in monocytes during fibrotic progression of myeloproliferative neoplasms

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)

Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)

Transfusion dependence is associated with poor survival in MDS-h and MDS-LB, while transplantation improves outcomes

Research on co-mutated genes in FLT3-ITD-positive acute myeloid leukemia

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Molecular and clinical characteristics of NUP98 rearrangements and their therapeutic responses in 6,000 patients with hematologic malignancies

The efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitor AND017 in NUP98-HOXD13transgenic mouse

Long-term treatment continuation of gecacitinib in myelofibrosis patients after ruxolitinib failure

Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A :: MLLT3 and U2AF1 mutation

The Implication of TP53 Allelic Status for Outcome and Erythropoiesis in MDS

Trial in Progress: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination with Azacitidine in Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes (AK117-205)

GATA1 Insufficiencies in Dysmegakaryopoiesis of Myelodysplastic Syndromes/Neoplasms

Impact of the 15-Item Frailty Scale in IPSS-R/IPSS-M Subgroup of Patients (Pts) with Myelodysplastic Syndromes (MDS)

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only